Protagen Closing in on Fourth Funding Round To Develop Biomarker-Based Diagnostics | GenomeWeb
Aiming to join the diagnostics field, German protein-analysis firm Protagen is preparing to close its fourth financing round to help it develop its diagnostics platform, its new CEO, Stefan Müllner, told ProteoMonitor this week.
 
The financing round is expected to close at the end of February, and though Müllner did not disclose the target amount, he said that the company will use the funds raised to initially develop diagnostics for prostate cancer and multiple sclerosis.  
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.